Valence Life Sciences: Proprietary Investment Strategy
Valence Life Sciences is the only life sciences venture firm with a proven track record of success in late-stage investing.
Experienced team has insight on what drives success from assessing management and clinical development plans for over 25 years
Disciplined and successful approach that has established Valence Advantage's reputation as a preferred investor for late-stage private and micro-cap public companies
Insight on what drives success is key to assessing management and their clinical plan
RECENT VALENCE NEWS
May 22, 2020
CalciMedica Raises $15 Million in Series C Financing Round Led by Valence Life Sciences
May 20, 2020
Atea Pharmaceuticals Announces IND Clearance of AT-527 for COVID-19 and $215 Million Financing
January 23, 2020
December 9, 2019